Biomerieux SA operates in the Diagnostic substances sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Biomerieux SA with three other
pharmaceutical manufacturers in Europe:
of the United Kingdom
sales of £447.50 million [US$548.41 million]
of which 37%
was Licensing & Biotechnology),
(871.90 million Euro [US$926.57 million]
Dechra Pharmaceuticals PLC
based in the United Kingdom
(£247.56 million [US$303.38 million]
of which 76%
was European Pharmaceuticals).
Biomerieux SA reported sales of 2.10 billion Euro (US$2.24 billion)
December of 2016.
increase of 7.1%
versus 2015, when the company's sales were 1.96 billion Euro.
Sales at Biomerieux SA have increased during each of the previous five years
(and since 2011, sales have increased a total of 47%).